In addition, this role of the NLRC4 inflammasome in gut inflammation bolsters the possible use of an LRRK2 inhibitor as an effective treatment for Crohn’s disease inasmuch as the inhibitor blocks the detrimental effect of IL-1β on epithelial permeability while it preserves the support of IL-18 in epithelial barrier function (43). Here, LRRK2 is linked to Crohn disease.